SELLAS Life Sciences Group
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7 Times Sq Ste 2503, New York City, New ...Phone Number
(646) 200-5278Website
www.sellaslifesciences.comRevenue
<$5 MillionStock Symbol
SLSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
4
1
1
1
1
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies and therapeutics for a broad range of cancer indications. The Company's lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. SELLAS is headquartered in New York, NY.Explore more
SELLAS Life Sciences Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SELLAS Life Sciences Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SELLAS Life Sciences Group had a recent Job posting/layoffs
Check out if SELLAS Life Sciences Group is spiking on competitors!
Earning: See what the market has to say on SELLAS Life Sciences Group recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if SELLAS Life Sciences Group has recently received funding, and reach out quickly before it becomes old news!
SELLAS Life Sciences Group, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once SELLAS Life Sciences Group has new funding data
Congratulate Masked Content for being promoted to Masked Content at SELLAS Life Sciences Group
Product Launch: Get notified when SELLAS Life Sciences Group launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to SELLAS Life Sciences Group
Compare insights from companies similar to SELLAS Life Sciences Group, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SELLAS Life Sciences Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SELLAS Life Sciences Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SELLAS Life Sciences Group.
SELLAS Life Sciences Group financials insights
Gather financial insights about SELLAS Life Sciences Group, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$20M
SELLAS Life Sciences Group Tech Stack
A closer look at the technologies used by SELLAS Life Sciences Group
Most Recent Scoops
Project
SELLAS Life Sciences Group has partnered with Hanger Clinic (900 locations), Equal ForMotion (part of Embla Medical/Ossur), and Ottobock Care (50 US locations) to distribute the MyoPro device through the O&P channel.
Earnings
SELLAS Life Sciences Group has reported revenue of $10.1 million for Q1 2026, with Q2 2026 guidance of approximately $10.8 million and full-year 2026 guidance reaffirmed at $43 million to $46 million.
Earnings, Finance
Earnings
reported a cash balance of approximately $15.8 million at the end of Q1, with cash burn of approximately $2.7 million in Q1, down year-over-year, and a target annual cash burn of approximately $9 million for 2026, approximately half of the prior year's burn of just under $18 million.
Accounting, Financial Reporting, Business Finance, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
SELLAS Life Sciences Group News & Media
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –SELLAS Life Sciences Group Inc. (SLS) Making Progress on Key Acute Myeloid Leukemia Treatment
Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On March 19, Chief Executive Officer Angelos Stergiou reiterated that 2026 is poised to be a pivotal year for Sellas Life Sciences Group Inc. (NASDAQ:SLS). The remarks align with the significant progress the company is […]SELLAS Life Sciences (SLS) to Present SLS009 Data at AACR 2026
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) is one of the popular penny stocks on Robinhood to buy. On March 17, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced that it will present preclinical data on SLS009 at the American Association for Cancer Research annual meeting on April 21, 2026. SLS009, alternatively known as tambiciclib, is a […]SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SELLAS Life Sciences Group
Sign Up For FreeTo access detailed company insights
SELLAS Life Sciences Group is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies and therapeutics for a broad range of cancer indications. The Company's lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad... Read More
